The safety profile of imatinib in CML and GIST: long-term considerations.
about
Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementSafety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study.Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for managementTargeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells.ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Pigmented villonodular synovitis: current concepts about diagnosis and management.Controversies in the management of gastrointestinal stromal tumors.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets.Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment.Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets.Cardiovascular differentiation of imatinib and bosutinib in the rat.
P2860
Q28075963-1F263B0A-B4C3-482C-B16C-0B7A02915F01Q30891587-F6B71854-D0A4-41D1-80B5-868097C69CEAQ33420661-29E9AE91-87CB-4AB8-A779-0C2607DA230EQ35140171-A3CF5F36-72AF-4E53-95BB-63D9B24AF38FQ35600421-97F53008-2A83-442D-AF6E-8216EF5019A9Q35607790-543FEC32-8378-4A71-BED9-FA88D7B46EA4Q36721667-CADD4FEE-E101-4A57-A87F-C0231B9F2E4EQ37652283-D58E19D4-9EBF-43FA-8625-F9397A298EC2Q37729245-8A2435CC-07B8-43E2-8B0D-77A42DA9BD31Q38150874-C6AF7821-2A97-45A5-9F1F-90F0D9CA66AEQ38199797-2E352CF4-50F7-4190-94EC-373605250060Q38729029-78D1A9DF-8170-43C0-AA81-D9F59D375B8EQ39182941-971D6B3D-03A8-4769-BCBF-BC698BB524CDQ42141583-3F719F81-CE9F-48FA-87AC-405C54BAD3F5Q47655848-462CF533-65A3-4B6B-9E2A-2412150584E8Q51191703-FFA0AA24-6278-44B0-B888-1A61E873D92E
P2860
The safety profile of imatinib in CML and GIST: long-term considerations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The safety profile of imatinib in CML and GIST: long-term considerations.
@en
The safety profile of imatinib in CML and GIST: long-term considerations.
@nl
type
label
The safety profile of imatinib in CML and GIST: long-term considerations.
@en
The safety profile of imatinib in CML and GIST: long-term considerations.
@nl
prefLabel
The safety profile of imatinib in CML and GIST: long-term considerations.
@en
The safety profile of imatinib in CML and GIST: long-term considerations.
@nl
P2860
P1476
The safety profile of imatinib in CML and GIST: long-term considerations.
@en
P2093
Eirini Thanopoulou
Ian Judson
P2860
P2888
P356
10.1007/S00204-011-0729-7
P577
2011-06-30T00:00:00Z